Dr Meike Heurich-Sevcenco

2021

• Baker, A. T.et al. 2021. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances 7(49), article number: eabl8213. (10.1126/sciadv.abl8213)
• Pathare, N.et al. 2021. Plasma IgM levels differentiate between survivors and non-survivors of culture-positive and culture-negative sepsis and SIRS: a pilot study. Journal of Clinical Medicine 10(22), article number: 5391. (10.3390/jcm10225391)
• Heurich, M.et al. 2021. Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis. Molecular Psychiatry (10.1038/s41380-021-01197-9)
• Flude, B. M.et al. 2021. Targeting the complement serine protease MASP-2 as a therapeutic strategy for coronavirus infections. Viruses 13(2), article number: 312. (10.3390/v13020312)
• Mongan, D.et al. 2021. Development of proteomic prediction models for transition to psychotic disorder in the clinical high-risk state and psychotic experiences in adolescence. JAMA Psychiatry 78(1), pp. 77-90. (10.1001/jamapsychiatry.2020.2459)

2019

• Madrid-Gambin, F.et al. 2019. Integrated lipidomics and proteomics point to early blood-based changes in childhood preceding later development of psychotic experiences: evidence from the Avon Longitudinal Study of Parents and Children. Biological Psychiatry 86(1), pp. 25-34. (10.1016/j.biopsych.2019.01.018)
• Föcking, M.et al. 2019. Complement pathway changes at age 12 are associated with psychotic experiences at age 18 in a longitudinal population-based study: evidence for a role of stress. Molecular Psychiatry 26, pp. 524-533. (10.1038/s41380-018-0306-z)

2016

• Heurich-Sevcenco, M.et al. 2016. Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research 145, pp. 84-92. (10.1016/j.thromres.2016.07.017)

2015

• Martínez-Barricarte, R.et al. 2015. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Molecular Immunology 66(2), pp. 263-273. (10.1016/j.molimm.2015.03.248)
• Szakmany, T. and Heurich-Sevcenco, M. 2015. Immunomodulation in sepsis - why blunting the response doesn't work?. Journal of Infection 71(2), pp. 147-149. (10.1016/j.jinf.2015.04.019)

2014

• Ruseva, M. and Heurich-Sevcenco, M. 2014. Purification and characterization of human and mouse complement C3. In: Gadjeva, M. ed. The Complement System: Methods and Protocols., Vol. 1100. Methods in Molecular Biology Humana Press, pp. 75-91., (10.1007/978-1-62703-724-2_6)

2013

• Heurich, M., Altintas, Z. and Tothill, I. 2013. Computational Design of Peptide Ligands for Ochratoxin A. Toxins 5(6), pp. 1202-1218. (10.3390/toxins5061202)

2012

• Harris, C. L.et al. 2012. The complotype: dictating risk for inflammation and infection. Trends in Immunology 33(10), pp. 513-521. (10.1016/j.it.2012.06.001)

2011

• Heurich, M.et al. 2011. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proceedings of the National Academy of Sciences of the United States of America 108(21), pp. 8761-8766. (10.1073/pnas.1019338108)

2010

• Martínez-Barricarte, R.et al. 2010. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. Journal of Clinical Investigation 120(10), pp. 3702-3712. (10.1172/JCI43343)